Shop

Author at Microdose

Madison Roberts

Madison Roberts is a nomadic journalist exploring the intersections of cutting-edge science, tech and human well-being. She immerses in diverse cultures, uncovering compelling stories in biotech, neuropsychiatry, neuroscience, mental health, psychedelics and longevity research. Her writing blends scientific rigor with human narratives, resonating across readers. Passionate about the brain's intricacies and psychedelics' healing potential, she's a thought-provoking, empathetic storyteller. Between interviews and breakthroughs, Madison cherishes tranquil moments exploring new landscapes.

Breaking News

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts

Culture, Industry, Psychedelic Groundbreakers

10 Oct 2025

After the Billion-Dollar Psychedelic Bet: Who’s Next for Big Pharma?

In the wake of Gilgamesh’s billion-dollar exit, a new wave of companies is emerging, smaller, stealthier, and far more scientifically disciplined than their first-wave predecessors. Their mission: harness the therapeutic...

By Madison Roberts

Law & Politics

23 Sep 2025

Psylutions and the DEA

In August 2025, the psychedelics movement crossed an unprecedented threshold. The U.S. Drug Enforcement Administration (DEA) announced that it would forward a petition to reschedule psilocybin, the psychoactive compound found...

By Madison Roberts

Breaking News

16 Sep 2025

With big pharma circling psychedelics, the next breakthrough may not come from tripping at all

When AbbVie moved to acquire Gilgamesh Pharmaceuticals in a deal valued at more than $1 billion, it sent shockwaves through the biotech community. For years, psychedelic-inspired drug development has been...

By Madison Roberts

Join Our Newsletter for Exclusive Updates, Stories, and More

Breaking News, Culture

9 Sep 2025

Global Psychedelic Week Announces In-Person Events

The inaugural Global Psychedelic Week, taking place November 3–9, 2025, brings together thought leaders, activists, and enthusiasts from over 100 countries. Featuring a hybrid model of online sessions and in-person...

By Madison Roberts

Breaking News, Press Releases, Psychedelic Groundbreakers, Psychedelic Titans, Science

28 Aug 2025

AbbVie’s $1B Psychedelic Bet: Who’s Next in the Neuroplastogen Gold Rush?

AbbVie’s quiet acquisition of Gilgamesh Pharmaceuticals, reportedly worth close to $1 billion, did more than make headlines. It signaled something far more significant: Big Pharma has officially entered the psychedelic-adjacent...

By Madison Roberts

Breaking News, Health & Wellness, Industry, Psychedelic Groundbreakers, Psychedelic Titans, Science

18 Aug 2025

Enveric Biosciences: Poised to Outshine Traditional Psychedelic Targets

But while traditional psychedelic developers dominate headlines, Enveric Biosciences (NASDAQ: ENVB) has stayed quietly in the background, focusing on an equally groundbreaking, but less flashy, approach: non-hallucinogenic neuroplastogens, small molecules...

By Madison Roberts

Breaking News, Industry, Press Releases, Psychedelic Groundbreakers, Science

23 Jul 2025

Enveric’s Latest Patent Signals a Clear Path Forward for PTSD Drug Development

This week, Enveric announced it has received a second U.S. patent allowance for compounds in its EVM401 Series, expanding its growing intellectual property fortress. These aren’t just any molecules —...

By Madison Roberts

Breaking News, Health & Wellness, Industry, Press Releases, Psychedelic Groundbreakers, Psychedelic Titans, Science

15 Jul 2025

Enveric’s EB-003 Shows Promise in PTSD Model, Offering a New Direction in Trauma Treatment

Enveric Biosciences announced that its lead compound, EB-003, significantly reduced trauma-related fear behaviors in a preclinical PTSD model—highlighting its potential as a fast-acting, non-hallucinogenic treatment for a condition with few...

By Madison Roberts

Follow us on social

Latest News

Reading the Brain’s Response: Enveric’s EB-003 Takes a Step Toward Human Testing

The Cost of Waiting: What Compass’s Depression Survey Means for Psychedelic Medicine

Beyond the Psychedelic Experience: Enveric Biosciences Takes Another Step Toward a New Generation of Mental Health Treatments

You Might Also Like

11 Aug 2026

Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High

Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the antidepressant benefits people associate with psychedelics without the trip? On...

By Madison Roberts

28 Jul 2026

FDA’s New Psychedelic Guidance Signals a Maturing Industry. Now Comes the Hard Part.

For years, the psychedelic medicine industry has operated in largely uncharted regulatory territory. Companies developing psilocybin, LSD, MDMA, and next-generation psychedelic-inspired compounds have often found themselves navigating a clinical landscape...

By Madison Roberts

13 Jul 2026

The Psychedelic Sector Has Grown Up. Wall Street Just Hasn’t Fully Realized It Yet

The sector experienced an early wave of enthusiasm fueled by bold promises, lofty valuations, and the belief that psychedelic medicine would quickly transform mental healthcare. Reality, however, proved more complicated....

By Madison Roberts

28 May 2026

Medical Psilocybin Act

New York lawmakers are officially considering the “Medical Psilocybin Act,” legislation that would create legal access to psilocybin therapy for conditions like PTSD, treatment-resistant depression, substance use disorders, end-of-life distress,...

By Madison Roberts

5 May 2026

PTSD, Policy Shifts, and the Rise of Neuroplastogens: What Enveric’s Latest Data Signals for the Field

By Madison Roberts

21 Apr 2026

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

President Donald Trump’s April 2026 executive order on accelerating treatments for serious mental illness does something the psychedelic industry has been waiting for, and quietly fearing. It removes ambiguity. For...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.